Coronavirus Notebook: Emergency Use Authorization For Blood Plasma Therapy, Pandemic Workloads, US FDA Offices, Rx Mail Deliveries
US FDA issues controversial use emergency authorization for blood plasma therapy while agency officials note workloads nearly double under coronavirus treatment acceleration program. This and more in the Pink Sheet's latest coronavirus update.
You may also be interested in...
Shah, deputy commissioner for medical and scientific affairs, has been overseeing FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. His departure the week of 20 January follows that of FDA Chief Counsel Amy Amin, whose resignation led to dueling appointments to temporarily fill her post.
Coronavirus Update: After Trump Pressure, US FDA Issues Emergency Use Authorization For Blood Plasma Therapy
US FDA Commissioner Stephen Hahn cites 35% improvement in study, but critics are dismayed by fudging of science and political pressure.
Clinical trials would have to move outside US if agency issues emergency use authorization for convalescent plasma, NYU prof says; experts disagree on whether the FDA should issue EUA.